Literature DB >> 10329205

Pentoxifylline inhibits PDGF-induced proliferation of and TGF-beta-stimulated collagen synthesis by vascular smooth muscle cells.

Y M Chen1, K D Wu, T J Tsai, B S Hsieh.   

Abstract

There is growing evidence that pentoxifylline (PTX) may have potential value as an antiproliferative and antifibrogenic agent. To assess whether this drug may be of use in the prevention of atherosclerosis or restenosis after angioplasty, we investigated the ability of PTX to inhibit proliferation and collagen synthesis in rat vascular smooth muscle cells (VSMCs) under both basal and platelet-derived growth factor (PDGF)- or transforming growth factor-beta (TGF-beta)- stimulated conditions. Intracellular cyclic AMP (cAMP) and cyclic GMP (cGMP) levels were measured in confluent cells using enzyme immunoassay kits. Cell proliferation was measured by methyltetrazolium assay. Cell cycle distribution was determined by flow cytometry. Total collagen synthesis was measured by 3H-proline incorporation assay. Expression of collagen alpha 1(I) and collagen alpha 1(III) mRNAs was detected by northern blotting. Addition of PTX to VSMC cultures suppressed both basal and PDGF-AB (25 ng/ml)-driven cell proliferation, in conjunction with a cell cycle blockade at the G1/S phase at 24 h. This effect was predominantly cAMP-dependent, as PTX increased cAMP in a dose-dependent manner (0.03 to 0.33 mg/ml) but not cGMP level, and the addition of dibutyryl-cAMP (0.2 to 2 m m) closely mimicked the effect of PTX. Furthermore, co-incubation with a selective inhibitor of cAMP-dependent protein kinase (PKA), H-89 (2.0 microm), or an N -myristoylated PKA pseudosubstrate nonapeptide, m-phi PKA (10 microm), prevented the antimitogenic effect of PTX. PTX also suppressed both basal and TGF- beta 1-augmented collagen alpha 1(I) and collagen alpha 1(III) mRNA levels beginning at 24 h, and attenuated both basal and TGF-beta 1 (5 ng/ml)-stimulated total collagen synthesis at 48 h. Co-incubation with H-89 or m-phi PKA reversed PTX-attenuated collagen alpha 1(I) and collagen alpha 1(III) mRNA levels at 24 h. These data suggest that the antimotigenic and anticollagen effects of PTX were mediated predominantly through a cAMP-PKA effector pathway. The dual effect of PTX on VSMC proliferation and collagen synthesis may form the rationale for animal or clinical trials for the treatment of vascular occlusion due to atherosclerosis and restenosis following angioplasty. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329205     DOI: 10.1006/jmcc.1998.0910

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  15 in total

1.  Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction.

Authors:  Maarten Albersen; Thomas M Fandel; Haiyang Zhang; Lia Banie; Guiting Lin; Dirk De Ridder; Ching-Shwun Lin; Tom F Lue
Journal:  Eur Urol       Date:  2010-10-26       Impact factor: 20.096

Review 2.  Potential approaches to reverse or repair renal fibrosis.

Authors:  Desiree Tampe; Michael Zeisberg
Journal:  Nat Rev Nephrol       Date:  2014-02-11       Impact factor: 28.314

3.  Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: Interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1.

Authors:  Guiting Lin; Alan W Shindel; Lia Banie; Hongxiu Ning; Yun-Ching Huang; Gang Liu; Ching-Shwun Lin; Tom F Lue
Journal:  J Sex Med       Date:  2010-04-01       Impact factor: 3.802

4.  Cyclic nucleotide phosphodiesterase 1 regulates lysosome-dependent type I collagen protein degradation in vascular smooth muscle cells.

Authors:  Yujun Cai; Clint L Miller; David J Nagel; Kye-Im Jeon; Soyeon Lim; Pingjin Gao; Peter A Knight; Chen Yan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-12-09       Impact factor: 8.311

5.  Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappa B down-regulation.

Authors:  Yung-Ming Chen; Chao-Jung Tu; Kung-Yu Hung; Kwan-Dun Wu; Tun-Jun Tsai; Bor-Shen Hsieh
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

6.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

7.  Angiopoietin-2-induced arterial stiffness in CKD.

Authors:  Fan-Chi Chang; Wen-Chih Chiang; Ming-Hsuan Tsai; Yu-Hsiang Chou; Szu-Yu Pan; Yu-Ting Chang; Pei-Ying Yeh; Yi-Ting Chen; Chih-Kang Chiang; Yung-Ming Chen; Tzong-Shinn Chu; Kwan-Dun Wu; Shuei-Liong Lin
Journal:  J Am Soc Nephrol       Date:  2014-02-07       Impact factor: 10.121

8.  Renin cells with defective Gsα/cAMP signaling contribute to renal endothelial damage.

Authors:  Anne Steglich; Friederike Kessel; Linda Hickmann; Michael Gerlach; Peter Lachmann; Florian Gembardt; Mathias Lesche; Andreas Dahl; Anna Federlein; Frank Schweda; Christian P M Hugo; Vladimir T Todorov
Journal:  Pflugers Arch       Date:  2019-08-06       Impact factor: 3.657

9.  Effects of silymarin and pentoxifylline on matrix metalloproteinase-1 and -2 expression and apoptosis in experimental hepatic fibrosis.

Authors:  Eray Kara; Teoman Coşkun; Yavuz Kaya; Okan Yumuş; Seda Vatansever; Ahmet Var
Journal:  Curr Ther Res Clin Exp       Date:  2008-12

10.  GNAS haploinsufficiency leads to subcutaneous tumor formation with collagen and elastin deposition and calcification.

Authors:  Akio Sakamoto; Lee S Weinstein; Antonius Plagge; Michael Eckhaus; Gavin Kelsey
Journal:  Endocr Res       Date:  2009       Impact factor: 1.720

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.